Brian joined Mersana in June 2019, bringing significant biopharmaceutical business strategy, operational, finance, product development and commercialization experience from leading oncology companies. He became our Chief Financial Officer in October 2021. 

Prior to Mersana, he served as Vice President, ZEJULA Commercial at TESARO, Inc. with responsibility for the commercialization of niraparib, a PARP inhibitor developed to treat ovarian cancer. From 2009 to 2017, Brian held increasingly senior roles at Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda, including serving as a Vice President, Global Marketing and Global Brand Head, where he was responsible for the global launch of ixazomib, a drug developed to treat multiple myeloma. At Millennium and earlier in his career at Novartis, Brian held corporate development and strategy roles, and he was a leader in the life sciences practice of L.E.K. Consulting.

Brian holds a B.A. in biophysical chemistry from Dartmouth College and an M.B.A. from the Wharton School of the University of Pennsylvania.

Fun fact about Brian: In his free time, Brian enjoys hiking, rock climbing, and Star Wars. In fact, many people have said that Brian reminds them of Han Solo.